Apellis Pharmaceuticals has initiated the VALIANT study, a global Phase 3 clinical trial evaluating an investigational medication called pegcetacoplan (peg-set-a-koé-plan) for young people and adults with a diagnosis of C3G or MPGN*.
To be eligible for the study, participants must:
- Be at least 12 years old
- Be diagnosed with C3G or MPGN.
- Have significant proteinuria (protein in the urine) confirmed by urine collections during the screening process
- Have normal to moderately impaired kidney function, confirmed during the screening process
- Weigh 30kg to 100kg
- Be willing to use contraception during and for a period after the study
Additional criteria will be assessed at the research site to confirm eligibility.
Pegcetacoplan is an investigational, targeted C3-inhibitor. Investigational means that pegcetacoplan is not approved by any health authority for the treatment of C3G or MPGN. Talk to your doctor if you are interested in a clinical trial.
For more information, and to connect with a participating clinical trial site, email email@example.com or visit theVALIANTstudy.com.
*C3G – Complement 3 glomerulopathy; MPGN (or IC-MPGN) – immune-complex membranoproliferative glomerulonephritis